Cite
HARVARD Citation
Przepiorka, D. et al. (2020). FDA Approval Summary: Ruxolitinib for Treatment of Steroid‐Refractory Acute Graft‐Versus‐Host Disease. Oncologist. pp. e328-e334. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Przepiorka, D. et al. (2020). FDA Approval Summary: Ruxolitinib for Treatment of Steroid‐Refractory Acute Graft‐Versus‐Host Disease. Oncologist. pp. e328-e334. [Online].